"John's extensive CNS marketing and commercial experience will bea tremendous asset to ACADIA as we execute on our strategy to developand commercialize pimavanserin together with a strategic partner andprepare ACADIA to participate in the future commercialization ofpimavanserin within the U.S. neurology market," said Uli Hacksell,Ph.D., ACADIA's Chief Executive Officer.
Prior to joining ACADIA, Mr. Kaiser served as Director,Neuroscience Strategy and New Product Planning where he wasresponsible for the development of Eli Lilly's global neurosciencecommercial strategy. Previously, he held senior level positions inglobal commercial development, market research, and brand management.In these various roles, Mr. Kaiser was responsible for establishingthe business and brand strategy for Cymbalta(R), developing globalmarket research in support of the successful launch of Zyprexa(R), andmanaging the global Prozac(R) brand and associated marketingactivities. Earlier in his career at Lilly, he served as ManagingDirector of Eli Lilly Netherlands, and held a variety of positions inpharmaceutical sales and sales management. Mr. Kaiser earned aBachelors of Science in Pharmacy from the University of CincinnatiCollege of Pharmacy.
"I look forward to bringing my experiences and network to bear onthe development and commercialization of pimavanserin and ACADIA'sportfolio of neuroscience assets," said Mr. Kaiser. "These drugcandidates have the potential to offer patients with mental illnesssignificant opportunities for improved outcomes and quality of life."
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company utilizing innovativetechnology to fuel drug discovery and clinical development of noveltreatments for central nervous system disorders. ACADIA currently hasfive mid-to-late stage clinical programs as well as a portfolio ofpreclinical and discovery assets directed at diseases with large unmetmedical needs, including schizophrenia, Parkinson's disease psychosis,sleep maintenance insomnia, and neuropathic pain. All of the drugcandidates in ACADIA's product pipeline emanate from discoveries madeusing its proprietary drug discovery platform. ACADIA's corporateheadquarters is located in San Diego, California and it maintainsresearch and development operations in both San Diego and Malmo,Sweden.
Forward-Looking Statements
Statements in this press release that are not strictly historicalin nature are forward-looking statements. These statements include butare not limited to statements related to the benefits to be derivedfrom ACADIA's drug development programs, including the potentialbenefits to patients with mental illness, ACADIA's strategy toestablish a strategic partnership to develop and commercializepimavanserin and its strategy to participate in the futurecommercialization of pimavanserin within the U.S. neurology market.These statements are only predictions based on current information andexpectations and involve a number of risks and uncertainties. Actualevents or results may differ materially from those projected in any ofsuch statements due to various factors, including the risks anduncertainties inherent in drug discovery, development andcommercialization, and the fact that past results of clinical trialsmay not be indicative of future trial results. For a discussion ofthese and other factors, please refer to ACADIA's annual report onForm 10-K for the year ended December 31, 2006 as well as ACADIA'ssubsequent filings with the Securities and Exchange Commission. Youare cautioned not to place undue reliance on these forward-lookingstatements, which speak only as of the date hereof. This caution ismade under the safe harbor provisions of the Private SecuritiesLitigation Reform Act of 1995. All forward-looking statements arequalified in their entirety by this cautionary statement and ACADIAundertakes no obligation to revise or update this press release toreflect events or circumstances after the date hereof.
ACADIA Pharmaceuticals Inc.
Lisa Barthelemy, Director, Investor Relations
Uli Hacksell, Ph.D., Chief Executive Officer
(858) 558-2871